AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional backing from executives at Meta, OpenAI, and Wiz.
After years of chatbots and image generators, AI is finally leaving the screen. At CES 2026, that shift became impossible to ignore. The annual tech showcase in Las Vegas was dominated by “physical AI” and robotics, from Boston Dynamic’s…